Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05669014
Registration number
NCT05669014
Ethics application status
Date submitted
20/12/2022
Date registered
30/12/2022
Date last updated
6/06/2024
Titles & IDs
Public title
A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)
Query!
Scientific title
A Phase 2, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Daxdilimab Subcutaneous Injection in Adult Participants With Inadequately Controlled Dermatomyositis or Anti-synthetase Inflammatory Myositis.
Query!
Secondary ID [1]
0
0
2022-502810-10-00
Query!
Secondary ID [2]
0
0
HZNP-DAX-205
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Idiopathic Inflammatory Myositis
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Neurological
0
0
0
0
Query!
Other neurological disorders
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Daxdilimab
Treatment: Drugs - Placebo
Experimental: Daxdilimab - Daxdilimab will be administered by subcutaneous (SC) injection over a total of 44 weeks.
Placebo Comparator: Placebo - Matching placebo will be administered by SC injection over a total of 24 weeks, then will be administered active drug by SC injection up to Week 44
Treatment: Drugs: Daxdilimab
Participants will be administered daxdilimab by subcutaneous (SC) injection
Treatment: Drugs: Placebo
Participants will be administered identically matching placebo by SC injection over a total of 24 weeks, then participants will be given active treatment for the remainder of the study.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Efficacy of daxdilimab compared to placebo as measured by Total Improvement Score (TIS)
Query!
Assessment method [1]
0
0
TIS is a composite endpoint based on improvement in the 6 Disease Activity Core Set Measure (CSM) scores and range from 0 to 100 (2016 European League Against Rheumatism [EULAR]/American College of Rheumatology [ACR] Myositis Response Criteria) where a higher score is indicative of more improvement
Query!
Timepoint [1]
0
0
At Week 24
Query!
Secondary outcome [1]
0
0
Proportion of participants with improvement of TIS = 40 and without deterioration at 2 consecutive visits at 24 weeks
Query!
Assessment method [1]
0
0
TIS is a composite endpoint based on improvement in the 6 Disease Activity Core Set Measure (CSM) scores and range from 0 to 100 (2016 European League Against Rheumatism [EULAR]/American College of Rheumatology [ACR] Myositis Response Criteria) where a higher score is indicative of more improvement
Query!
Timepoint [1]
0
0
At 24 Weeks
Query!
Secondary outcome [2]
0
0
Proportion of participants with improvement of TIS = 20 and without deterioration at 2 consecutive visits at 24 weeks
Query!
Assessment method [2]
0
0
TIS is a composite endpoint based on improvement in the 6 Disease Activity Core Set Measure (CSM) scores and range from 0 to 100 (2016 European League Against Rheumatism [EULAR]/American College of Rheumatology [ACR] Myositis Response Criteria) where a higher score is indicative of more improvement
Query!
Timepoint [2]
0
0
At 24 Weeks
Query!
Secondary outcome [3]
0
0
Change in the cutaneous dermatomyositis disease area and severity index (CDASI) activity score from Baseline (Day 1) to Week 24
Query!
Assessment method [3]
0
0
The CDASI is used to assess the severity of cutaneous DM and detect improvement in disease activity. The scale rates disease involvement in 15 different body areas using 3 activity (erythema, scale, erosion/ulceration) and 2 damage (poikiloderma, calcinosis) measures. The activity score ranges from 0 to 100 and the damage score from 0 to 32. Higher scores indicate greater disease severity
Query!
Timepoint [3]
0
0
Baseline (Day1) to Week 24
Query!
Secondary outcome [4]
0
0
Proportion of participants on an oral corticosteroid (OCS) dose = 10 mg of prednisone or equivalent at baseline who achieve a clinically meaningful reduction in the OCS dose at Week 24
Query!
Assessment method [4]
0
0
A clinically meaningful reduction is measured as either a 25% decrease or an OCS dose of 7.5 mg/day of prednisone or equivalent
Query!
Timepoint [4]
0
0
Baseline to Week 24
Query!
Secondary outcome [5]
0
0
Serum concentration of daxdilimab over time
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Baseline to Week 56
Query!
Secondary outcome [6]
0
0
Proportion of the participants with anti-drug antibodies (ADA) positive post-baseline only or boosted their pre-existing ADA during the study period.
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Baseline to Week 56
Query!
Secondary outcome [7]
0
0
Incidence of ADA directed against daxdilimab over time
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Baseline to Week 56
Query!
Secondary outcome [8]
0
0
Titer of ADA to daxdilimab over time
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Baseline to Week 56
Query!
Secondary outcome [9]
0
0
Incidence of treatment emergent adverse events (TEAEs)
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Baseline to Week 56
Query!
Secondary outcome [10]
0
0
Incidence of treatment emergent serious adverse events (TESAEs)
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Baseline to Week 56
Query!
Secondary outcome [11]
0
0
Incidence of treatment emergent adverse events of special interest (TEAESIs)
Query!
Assessment method [11]
0
0
TEAESIs including hypersensitivity reactions, anaphylaxis, herpes zoster infection, severe [(common terminology criteria for adverse events (CTCAE)] Grade 3 or higher) viral infection/reactivation, opportunistic infection, and malignancy (except non melanoma skin cancer)
Query!
Timepoint [11]
0
0
Baseline to Week 56
Query!
Eligibility
Key inclusion criteria
Key
1. Adult men or women 18 and = 75 years of age at the time of signing the informed
consent (ICF).
2. A diagnosis of definite or probable myositis according to American College of
Rheumatology/European League Against Rheumatism 2017 (ACR/EULAR 2017) criteria:
1. Population 1: DM
- Diagnosis of DM with DM rash current or historical, or
2. Population 2: ASIM
- Anti-histidyl tRNA synthetase-(Anti-Jo-1) antibodies must be positive during
screening by central laboratory testing, or
- One of following antibodies must be positive by historical testing: directed
against anti-alanyl- (anti-PL-12), anti-threonyl-(anti PL-7),
anti-asparaginyl-(anti-KS), anti-glycyl-(anti-EJ), anti-isoleucyl-(anti-OJ),
anti-phenylalanyl-transfer RNA synthetase-(anti-ZO), anti-tyrosil-YRS(HA).
3. Currently active myositis with all the following (a, b, and c) during screening:
1. Manual Muscle Testing (MMT 8) score < 142
2. At least 2 other abnormal core set measures (CSM) from the following list:
- Patient global disease activity (PtGDA) = 2 cm in a 10 cm visual analog
scale (VAS)
- Physician's Global Disease Activity (PhGDA) = 2 cm in a 10 cm VAS
- Extramuscular activity = 2cm in a 10 cm VAS
- At least one muscle enzyme 1.5 times upper limit of normal (ULN)
- Health assessment questionnaire-disability index (HAQ-DI) = 0.5
3. Global muscle damage score = 5 on a 10 cm VAS on the myositis damage index (MDI).
4. Participants should be on stable standard of care therapy if tolerated; if they are
not able to tolerate it or have failed standard of care, medications should have a
washed out period.
5. Participants should be willing to taper corticosteroid dose per protocol when stable
or improving.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Any condition that, in the opinion of the investigator or sponsor, would interfere
with the evaluation of investigational product (IP) or interpretation of participant
safety or study results.
2. Weight > 160 kg (352 pounds) at screening.
3. Breastfeeding or pregnant women or women who intend to become pregnant anytime from
signing the ICF through 6 months after receiving the last dose of IP.
4. History of clinically meaningful cardiac disease including unstable angina, myocardial
infarction, congestive heart failure within 6 months prior to randomization;
arrhythmia requiring active therapy, except for clinically insignificant extra
systoles, or minor conduction abnormalities; or presence of clinically meaningful
abnormality on electrocardiogram (ECG) if, in the opinion of the Investigator, it
would increase the risk of study participation.
5. History of cancer within the past 5 years
6. Any underlying condition that in the opinion of the Investigator significantly
predisposes the participant to infection (eg. hepatitis C).
7. Known history of a primary immunodeficiency or an underlying condition, such as known
human immunodeficiency virus (HIV) infection, or a positive result for HIV infection
per central laboratory.
8. All participants will undergo testing for hepatitis B virus serology as defined in the
protocol.
9. Active tuberculosis (TB), or a positive interferon gamma (IFN-?) release assay (IGRA)
test at screening, unless documented history of appropriate treatment for active or
latent TB according to local guidelines.
10. Any severe herpes virus family infection (including Epstein-Barr virus,
cytomegalovirus [CMV]) at any time prior to randomization.
11. Opportunistic infection requiring hospitalization or parenteral antimicrobial
treatment within 2 years prior to randomization.
12. Significant organ system involvement or myositis damage (global muscle damage score >
5 on a 10 cm VAS scale on the MDI) that poses risks in the study or impedes
assessments.
13. Diagnosis of immune-mediated necrotizing myopathy (IMNM) [(positive
3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGR), anti-signal recognition
particle (anti- SRP), or antibody negative)], inclusion body myositis (IBM) (including
positive anti-cytosolic 5'-nucleotidase 1A (anti cN1A), or drug-induced myositis.
14. Current musculoskeletal, joint, or inflammatory disease, including significant joint
contractures or calcinosis that in the opinion of the investigator, could interfere
with the muscle strength assessments and confound the disease activity assessments.
15. Wheelchair bound participants.
16. Current inflammatory skin disease other than DM or ASIM that, in the opinion of the
investigator, could interfere with the inflammatory skin assessments or confound the
disease activity assessments.
17. Severe interstitial lung disease where respiratory symptoms limit participant function
or progressive pulmonary fibrosis.
18. Myositis in overlap with another connective tissue disease that precludes the accurate
assessment of a treatment response (for example, difficulty in assessing muscle
strength in a scleroderma patient with associated myositis).
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
4/12/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
22/05/2027
Query!
Actual
Query!
Sample size
Target
96
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Query!
Recruitment hospital [1]
0
0
Campbelltown Hospital - Campbelltown
Query!
Recruitment hospital [2]
0
0
Griffith University - Southport
Query!
Recruitment postcode(s) [1]
0
0
2560 - Campbelltown
Query!
Recruitment postcode(s) [2]
0
0
4222 - Southport
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Maryland
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Ohio
Query!
Country [6]
0
0
Brazil
Query!
State/province [6]
0
0
Minas Gerais
Query!
Country [7]
0
0
Brazil
Query!
State/province [7]
0
0
Paraná
Query!
Country [8]
0
0
Germany
Query!
State/province [8]
0
0
Baden-Württemberg
Query!
Country [9]
0
0
Italy
Query!
State/province [9]
0
0
Lombardia
Query!
Country [10]
0
0
Mexico
Query!
State/province [10]
0
0
Jalisco
Query!
Country [11]
0
0
Mexico
Query!
State/province [11]
0
0
Monterrey
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Amgen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary efficacy objective:
To evaluate the effect of daxdilimab compared with placebo in reducing disease activity at
Week 24.
The secondary efficacy objectives include:
1. To evaluate the effect of daxdilimab compared with placebo in reducing disease activity
at Week 24.
2. To evaluate the effect of daxdilimab compared with placebo on skin symptoms at Week 24.
3. To evaluate the effect of daxdilimab on decreasing the use of corticosteroid at Week 24.
Other secondary objectives include:
1. To characterize the pharmacokinetics (PK) and immunogenicity of daxdilimab in
participants.
2. To evaluate the safety and tolerability of daxdilimab in participants.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05669014
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
MD
Query!
Address
0
0
Amgen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Amgen Call Center
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
866-572-6436
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05669014
Download to PDF